Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common amino acid outperform chemotherapy cream to restore skin color?

NCT ID NCT07742982

Disease control Sponsor: Aswan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This trial tests whether applying tyrosine or 5-fluorouracil to the skin, combined with a fractional erbium YAG laser, can help restore color in people with focal vitiligo. Vitiligo is an autoimmune condition that causes white patches by destroying pigment-making cells. The study will measure changes in the Vitiligo Area Scoring Index to see which treatment works better. Around 40 adults with focal vitiligo will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Topical tyrosine or topical 5-fluorouracil, each combined with fractional erbium YAG laser
What this could lead to
If successful, this could point toward a more effective treatment to restore skin color in people with focal vitiligo.
What could go wrong
This is a small early-phase trial, so results may not apply broadly. Treatments may cause skin irritation or fail to produce lasting repigmentation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Patients with focal vitiligo Exclusion Criteria: * Pregnancy. * Lactation. * Patients with segmental vitiligo. * Patients with autoimmune disease including thyroiditis. * Patients with chronic systemic diseases,such as anemia ,diabetes mellitus, immunosuppression, or chronic infections. * Patients with active skin infections.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focal vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal vitiligo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aswan University Hospital

    RECRUITING

    Aswān, Egypt